Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.

MLA

Ocean AJ, et al. “Fractionated Radioimmunotherapy with (90) Y-Clivatuzumab Tetraxetan and Low-Dose Gemcitabine Is Active in Advanced Pancreatic Cancer: A Phase 1 Trial.” Cancer (0008543X), vol. 118, no. 22, Nov. 2012, pp. 5497–506. EBSCOhost, https://doi.org/10.1002/cncr.27592.

APA

Ocean AJ, Pennington KL, Guarino MJ, Sheikh A, Bekaii-Saab T, Serafini AN, Lee D, Sung MW, Gulec SA, Goldsmith SJ, Manzone T, Holt M, O’Neil BH, Hall N, Montero AJ, Kauh J, Gold DV, Horne H, Wegener WA, & Goldenberg DM. (2012). Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Cancer (0008543X), 118(22), 5497–5506. https://doi.org/10.1002/cncr.27592

Chicago

Ocean AJ, Pennington KL, Guarino MJ, Sheikh A, Bekaii-Saab T, Serafini AN, Lee D, et al. 2012. “Fractionated Radioimmunotherapy with (90) Y-Clivatuzumab Tetraxetan and Low-Dose Gemcitabine Is Active in Advanced Pancreatic Cancer: A Phase 1 Trial.” Cancer (0008543X) 118 (22): 5497–5506. doi:10.1002/cncr.27592.